Actively Recruiting
Three miRNA Signatures in Glioma: From Molecular Mechanisms to Potential Clinical Application
Led by Regina Elena Cancer Institute · Updated on 2025-03-19
10
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
Sponsors
R
Regina Elena Cancer Institute
Lead Sponsor
U
University of Roma La Sapienza
Collaborating Sponsor
AI-Summary
What this Trial Is About
Individual overexpression of the three miRNAs negatively affects cell viability and proliferation mainly in grade III IDH-wild type cells, while in higher grade cells, the effect is more pronounced when the entire signature is overexpressed, individual and combined overexpression of the signature members is able to determine a significant reduction in both migration and invasion. Therefore, ectopic expression of the miRNAs identified by us has a negative impact on cell viability, proliferation and apoptosis, but above all on migration and invasion.
CONDITIONS
Official Title
Three miRNA Signatures in Glioma: From Molecular Mechanisms to Potential Clinical Application
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histological diagnosis of glioma
- No presence of other primary tumors
- No metastatic disease
- Availability of surgical tumor tissue
- Written informed consent provided
You will not qualify if you...
- Histological diagnosis of non-glial tumor
- Presence of other solid tumors
- Metastatic disease
- No available surgical tumor tissue
- HIV positive status
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
"Regina Elena" National Cancer Institute
Rome, Italy, 00144
Actively Recruiting
Research Team
A
Ana Belen Diaz, Doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here